Miguel Angel Sanz

List of Publications by Year
in descending order

435	27,514	17674 60	6004 154
papers	citations	h-index	g-index

467	467	467	19310
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 2010, 115, 453-474.	1.4	3,009
2	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	1.4	2,214
3	International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010, 115, 168-186.	1.4	1,853
4	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation. New England Journal of Medicine, 2017, 377, 454-464.	30.7	1,715
5	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	30.7	1,533
6	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2009, 113, 1875-1891.	1.4	864
7	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, The, 2008, 371, 395-403.	12.2	797
8	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 133, 1630-1643.	1.4	427
9	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 2003, 103, 1237-1243.	1.4	399
10	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 2008, 111, 3395-3402.	1.4	313
11	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood, 1997, 90, 4710-4718.	1.4	307
12	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood, 2009, 113, 775-783.	1.4	296
13	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010, 115, 5137-5146.	1.4	282
14	Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood, 2001, 98, 2332-2338.	1.4	221
15	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood, 2019, 134, 924-934.	1.4	215
16	Modern Approaches to Treating Acute Promyelocytic Leukemia. Journal of Clinical Oncology, 2011, 29, 495-503.	5.3	203
17	Deep Infections Caused by Scedosporium prolificans: A Report on 16 Cases in Spain and a Review of the Literature. Medicine (United States), 1997, 76, 256-265.	1.1	198
18	Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica, 2008, 93, 67-74.	3.5	191

#	Article	IF	Citations
19	Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 2008, 111, 1078-1084.	1.4	157
20	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008, 112, 3130-3134.	1.4	156
21	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 2002, 11, 1391-1397.	3.0	141
22	How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood, 2014, 123, 2777-2782.	1.4	140
23	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	1.4	140
24	Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. British Journal of Haematology, 2001, 114, 174-176.	2.8	135
25	Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer. Cancer, 2003, 98, 1048-1054.	4.1	131
26	Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group. Journal of Clinical Oncology, 2005, 23, 7632-7640.	5.3	128
27	Acute promyelocytic leukemia.Therapy results and prognostic factors. Cancer, 1988, 61, 7-13.	4.1	126
28	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood, 2011, 117, 1799-1805.	1.4	121
29	Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer, 1985, 56, 2369-2375.	4.1	117
30	Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood, 2005, 105, 3019-3025.	1.4	116
31	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). Blood, 2015, 126, 6-6.	1.4	108
32	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, 2013, 121, 1935-1943.	1.4	105
33	Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries. Clinical Infectious Diseases, 2006, 43, e29-e38.	5.7	102
34	Pregnancy outcome in hematologic malignancies. Cancer, 1991, 67, 703-709.	4.1	100
35	Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica, 2008, 93, 921-924.	3.5	100
36	All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood, 2004, 104, 3490-3493.	1.4	98

#	Article	IF	Citations
37	Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leukemia Research, 2006, 30, 1471-1491.	1.1	95
38	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica, 2009, 94, 1242-1249.	3.5	93
39	Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene. Cancers, 2020, 12, 624.	3.9	93
40	Parsaclisib, a potent and highly selective PI3KÎ´ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood, 2019, 133, 1742-1752.	1.4	91
41	Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion, 2002, 42, 4-9.	1.9	88
42	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica, 2010, 95, 424-431.	3.5	85
43	Bone Marrow-Derived Cells from Male Donors Do Not Contribute to the Endometrial Side Population of the Recipient. PLoS ONE, 2012, 7, e30260.	2.4	85
44	Cord Blood Transplantation from Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 86-94.	2.1	80
45	THE DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF THE PETHEMA GROUP AND REVIEW OF THE LITERATURE.. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011059.	1.1	79
46	Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. Blood, 2008, 112, 918-918.	1.4	78
47	Reducedâ€intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the <scp>A</scp>cute <scp>L</scp>eukemia <scp>W</scp>orking <scp>P</scp>arty of the <scp>E</scp>uropean <scp>G</scp>roup for <scp>B</scp>lood and <scp>M</scp>arrow <scp>T</scp>ransplantation. Cancer, 2015, 121, 1048-1055.	4.1	78
48	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica, 2007, 92, 308-314.	3.5	77
49	What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?. Vaccines, 2020, 8, 183.	4.6	77
50	Bleeding and thrombosis in acute leukemia: What does the future of therapy look like?. Thrombosis Research, 2007, 120, S99-S106.	1.7	74
51	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood, 2008, 112, 3383-3390.	1.4	74
52	DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia. PLoS ONE, 2010, 5, e12197.	2.4	73
53	Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thrombosis Research, 2010, 125, S51-S54.	1.7	70
54	Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood, 2002, 100, 724-727.	1.4	69

#	Article	IF	Citations
55	Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leukemia and Lymphoma, 2006, 47, 1488-1494.	1.4	69
56	Exosomes derived from hucMSC attenuate renal fibrosis through CK1Î´/Î²-TRCP-mediated YAP degradation. Cell Death and Disease, 2020, 11, 327.	6.5	69
57	Acute Promyelocytic Leukemia: Recent Advances in Diagnosis and Management. Seminars in Oncology, 2008, 35, 401-409.	2.4	68
58	Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 2001, 114, 721-723.	2.8	67
59	Treatment of Acute Promyelocytic Leukemia. Hematology American Society of Hematology Education Program, 2006, 2006, 147-155.	2.6	66
60	A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood, 2011, 117, 242-245.	1.4	65
61	Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica, 2008, 93, 735-740.	3.5	63
62	Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. British Journal of Haematology, 2008, 77, 478-485.	2.8	60
63	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica, 2011, 96, 1470-1477.	3.5	60
64	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. Biology of Blood and Marrow Transplantation, 2013, 19, 69-74.	2.1	60
65	Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy, 2002, 50, 79-88.	3.2	58
66	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Annals of Hematology, 2014, 93, 2001-2010.	1.9	58
67	Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study. Transfusion and Apheresis Science, 2010, 43, 299-303.	1.0	56
68	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia, 2021, 35, 2539-2551.	7.5	56
69	Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 730-740.	2.1	54
70	Interfacial Domains in Sindbis Virus 6K Protein. Journal of Biological Chemistry, 2003, 278, 2051-2057.	3.5	53
71	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, 2022, 36, 90-99.	7.5	51
72	Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion, 2001, 41, 201-205.	1.9	50

#	Article	IF	Citations
73	Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo EspaÃ±ol de Trasplante Hematopoyetico. Biology of Blood and Marrow Transplantation, 2016, 22, 584-588.	2.1	49
74	Sindbis Virus Variant with a Deletion in the 6K Gene Shows Defects in Glycoprotein Processing and Trafficking: Lack of Complementation by a Wild-Type 6K Gene in trans. Journal of Virology, 2001, 75, 7778-7784.	3.4	48
75	Impact on Outcomes of Human Leukocyte AntigenÂMatching by Allele-Level Typing in Adults withÂAcute Myeloid Leukemia Undergoing Umbilical CordÂBlood Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 106-110.	2.1	48
76	Prognostic factors in myelodysplastic syndromes. Leukemia Research, 1992, 16, 77-86.	1.1	47
77	Cord-Blood Transplantation in Patients with Leukemia â€" A Real Alternative for Adults. New England Journal of Medicine, 2004, 351, 2328-2330.	30.7	47
78	Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica, 2011, 96, 1448-1456.	3.5	47
79	A Role for 3AB Protein in Poliovirus Genome Replication. Journal of Biological Chemistry, 1995, 270, 14430-14438.	3.5	46
80	Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurological Sciences, 2017, 38, 1213-1221.	2.0	46
81	A convergent approach to midpacamide and dispacamide pyrrole-imidazole marine alkaloids. Tetrahedron Letters, 2001, 42, 851-854.	1.4	45
82	Translation of Sindbis Virus 26S mRNA Does Not Require Intact Eukariotic Initiation Factor 4G. Journal of Molecular Biology, 2006, 355, 942-956.	4.3	45
83	BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia, 2021, 35, 1317-1329.	7.5	45
84	Dual Mechanism for the Translation of Subgenomic mRNA from Sindbis Virus in Infected and Uninfected Cells. PLoS ONE, 2009, 4, e4772.	2.4	44
85	Epigenetic regulation of the nonâ€canonical Wnt pathway in acute myeloid leukemia. Cancer Science, 2010, 101, 425-432.	4.0	44
86	A prognostic model for survival after salvage treatment with <scp>FLAG</scp>â€da +/â^' gemtuzumabâ€ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. British Journal of Haematology, 2016, 174, 700-710.	2.8	44
87	Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia, 2018, 32, 1671-1678.	7.5	44
88	Prognostic factors in chronic myelodysplastic syndromes: A multivariate analysis in 107 cases. American Journal of Hematology, 1988, 27, 163-168.	4.3	43
89	Recomendaciones sobre el tratamiento de la enfermedad fÃºngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad EspaÃ±ola de Enfermedades Infecciosas y MicrobiologÃa ClÃnica (SEIMC). ActualizaciÃ³n 2011. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 435-454.	0.6	42
90	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leukemia Research, 2002, 26, 725-730.	1.1	41

#	Article	IF	Citations
91	The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leukemia Research, 2007, 31, 947-953.	1.1	40
92	A phase Iâ€“II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Annals of Hematology, 2018, 97, 763-772.	1.9	40
93	Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Annals of Hematology, 2014, 93, 299-307.	1.9	39
94	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 358-366.	2.1	39
95	Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?. Transfusion, 2001, 41, 106-110.	1.9	38
96	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with allâ€‹trans retinoic acid and arsenic trioxide. British Journal of Haematology, 2015, 171, 471-477.	2.8	38
97	Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. Leukemia Research, 2013, 37, 1690-1696.	1.1	37
98	Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Annals of Hematology, 2014, 93, 1421-2.	1.9	37
99	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2015, 100, 683-689.	3.5	37
100	Valorization of Carob's Germ and Seed Peel as Natural Antioxidant Ingredients in Gluten-Free Crackers. Journal of Food Processing and Preservation, 2017, 41, e12770.	2.0	37
101	Viral Translation Is Coupled to Transcription in Sindbis Virus-Infected Cells. Journal of Virology, 2007, 81, 7061-7068.	3.4	36
102	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	5.5	36
103	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. Biology of Blood and Marrow Transplantation, 2010, 16, 957-966.	2.1	35
104	Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. Journal of Hematology and Oncology, 2017, 10, 31.	17.8	35
105	Advances in the management of coagulopathy in acute promyelocytic leukemia. Thrombosis Research, 2020, 191, S63-S67.	1.7	35
106	Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. European Journal of Haematology, 2010, 85, 363-365.	2.3	34
107	Myeloablative Cord Blood Transplantation in Adults with Acute Leukemia: Comparison of Two Different Transplant Platforms. Biology of Blood and Marrow Transplantation, 2013, 19, 1725-1730.	2.1	34
108	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia, 2021, 35, 2358-2370.	7.5	34

#	Article	IF	Citations
109	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood, 2010, 116, 5650-5659.	1.4	33
110	Analysis of t(15;17) chromosomal breakpoint sequences in therapyâ€related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at PML and RARA loci. Genes Chromosomes and Cancer, 2010, 49, 726-732.	3.4	33
111	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Annals of Hematology, 2015, 94, 1347-1356.	1.9	33
112	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. Annals of Hematology, 2017, 96, 1449-1456.	1.9	33
113	The Initiation Factors eIF2, eIF2A, eIF2D, eIF4A, and eIF4G Are Not Involved in Translation Driven by Hepatitis C Virus IRES in Human Cells. Frontiers in Microbiology, 2018, 9, 207.	3.6	33
114	PROGNOSTIC VALUE OF CD34 EXPRESSION IN DE NOVO ACUTE MYELOBLASTIC LEUKAEMIA. British Journal of Haematology, 1991, 79, 533-534.	2.8	32
115	Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expression. Clinica Chimica Acta, 2008, 395, 120-123.	1.6	32
116	Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. Haematologica, 2009, 94, 827-832.	3.5	32
117	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2014, 99, 1380-1386.	3.5	32
118	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplantation, 2020, 55, 2147-2159.	2.5	32
119	Positive selection for CD34 + reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2003, 31, 545-550.	0.5	31
120	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica, 2011, 96, 1557-1559.	3.5	31
121	Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 305-318.	0.4	31
122	Single-Unit Umbilical Cord Blood Transplantation fromÂUnrelated Donors in Adult Patients with Chronic Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 1589-1595.	2.1	30
123	Requirements for eIF4A and eIF2 during translation of Sindbis virus subgenomic mRNA in vertebrate and invertebrate host cells. Cellular Microbiology, 2013, 15, 823-840.	2.3	30
124	Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2015, 21, 755-760.	2.1	30
125	Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo EspaÃ±ol De Trasplante de Medula Osea en NiÃ±os (GETMON) and the Grupo EspaÃ±ol de Trasplante Hematopoyetico (GETH). Transfusion Medicine Reviews, 2018, 32, 179-185.	2.1	30
126	Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1818-1824.	2.1	30

#	Article	IF	Citations
127	Identification of Risk Factors for Tumour Lysis Syndrome in Patients with Acute Myeloid Leukaemia: Development of a Prognostic Score.. Blood, 2005, 106, 1843-1843.	1.4	30
128	Central nervous system involvement at first relapse in patients with acute myeloid leukemia. Haematologica, 2011, 96, 1375-1379.	3.5	29
129	High Î”Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood, 2015, 126, 2302-2306.	1.4	29
130	Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. SHORT REPORT. British Journal of Haematology, 2000, 111, 708-710.	2.8	29
131	Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. Best Practice and Research in Clinical Haematology, 2003, 16, 433-451.	1.9	28
132	Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value in Health, 2011, 14, 90-96.	0.3	28
133	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica, 2015, 100, 1294-1300.	3.5	28
134	De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19. Genes Chromosomes and Cancer, 2003, 36, 406-412.	3.4	27
135	Translation without eIF2 Promoted by Poliovirus 2A Protease. PLoS ONE, 2011, 6, e25699.	2.4	26
136	Pharmacogenomics and the Treatment of Acute Myeloid Leukemia. Pharmacogenomics, 2016, 17, 1245-1272.	1.4	26
137	DiagnÃ³stico, tratamiento y seguimiento de la trombocitopenia inmune primaria. Medicina ClÃnica, 2012, 138, 261.e1-261.e17.	0.6	25
138	A scoring system to predict the risk of death during induction with anthracycline plus cytarabineâ€based chemotherapy in patients with de novo acute myeloid leukemia. Cancer, 2012, 118, 410-417.	4.1	25
139	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1387-1392.	2.1	25
140	Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia. Oncologist, 2005, 10, 806-814.	4.1	24
141	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leukemia and Lymphoma, 2009, 50, 216-222.	1.4	24
142	Rapid Detection of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia Using High-Resolution Melting Analysis. Journal of Molecular Diagnostics, 2009, 11, 458-463.	3.0	24
143	Translation of Viral mRNA without Active eIF2: The Case of Picornaviruses. PLoS ONE, 2011, 6, e22230.	2.4	24
144	Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia. Annals of Hematology, 2015, 94, 1357-1361.	1.9	24

#	Article	IF	Citations
145	Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigenâ€"Matched Sibling Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 134-139.	2.1	24
146	Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. Current Drug Metabolism, 2018, 19, 55-74.	1.3	24
147	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. Journal of Molecular Diagnostics, 2019, 21, 228-240.	3.0	24
148	Translation Directed by Hepatitis A Virus IRES in the Absence of Active eIF4F Complex and eIF2. PLoS ONE, 2012, 7, e52065.	2.4	24
149	The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations. PLoS ONE, 2016, 11, e0148346.	2.4	24
150	Acute Myeloblasts Leukemia with Minimal Myeloid Differentiation (FAB AML-M0): A Study of Eleven Cases. Leukemia and Lymphoma, 1993, 12, 103-108.	1.4	23
151	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. British Journal of Haematology, 2005, 129, 791-794.	2.8	23
152	Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica, 2011, 96, 621-625.	3.5	23
153	Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2018, 97, 161-167.	1.9	23
154	Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 189-201.	1.0	23
155	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. Blood, 2019, 134, 951-959.	1.4	22
156	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. Leukemia and Lymphoma, 2021, 62, 2928-2938.	1.4	22
157	Rapid detection of the major Mediterranean Î²-thalassaemia mutations by real-time polymerase chain reaction using fluorophore-labelled hybridization probes. British Journal of Haematology, 2002, 119, 554-557.	2.8	21
158	Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. Annals of Hematology, 2004, 83, 687-690.	1.9	21
159	Translation Driven by Picornavirus IRES Is Hampered from Sindbis Virus Replicons: Rescue by Poliovirus 2A Protease. Journal of Molecular Biology, 2010, 402, 101-117.	4.3	21
160	In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene. Annals of Hematology, 2014, 93, 1931-1933.	1.9	21
161	Outcome of older (â‰¥70 years) APL patients frontline treated with or without arsenic trioxideâ€"an International Collaborative Study. Leukemia, 2020, 34, 2333-2341.	7.5	21
162	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. Bone Marrow Transplantation, 2021, 56, 1272-1280.	2.5	21

#	Article	IF	Citations
163	PLZF-RARÎ±, NPM1-RARÎ±, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. Cancers, 2020, 12, 1313.	3.9	21
164	Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology, 2011, 16, 274-277.	1.6	20
165	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica, 2015, 100, e183-e185.	3.5	20
166	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	13.2	20
167	DisseminatedBlastoschizomyces capitatus infection in acute myeloblastic leukaemia. Supportive Care in Cancer, 1996, 4, 291-293.	2.3	19
168	Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion, 2002, 42, 1384-1385.	1.9	19
169	Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia. Advances in Hematology, 2009, 2009, 1-4.	1.1	19
170	Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 1744-1750.	2.1	19
171	Transfusion Management and Immunohematologic Complications in Liver Transplantation: Experience of a Single Institution. Transfusion Medicine and Hemotherapy, 2015, 42, 8-14.	1.5	19
172	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of postâ€transplant lymphoproliferative disease. European Journal of Haematology, 2016, 96, 128-135.	2.3	19
173	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Annals of Hematology, 2019, 98, 2081-2088.	1.9	19
174	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Advances, 2021, 5, 760-770.	5.5	19
175	Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim in Two Phase 3 Placebo-Controlled Clinical Trials.. Blood, 2009, 114, 891-891.	1.4	19
176	Identification of two atypical PMLâ€“RARÎ± transcripts in two patients with acute promyelocytic leukemia. Leukemia Research, 2002, 26, 439-442.	1.1	18
177	OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012011.	1.1	18
178	Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia. Annals of Hematology, 2012, 91, 1855-1860.	1.9	18
179	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. Expert Review of Clinical Pharmacology, 2019, 12, 197-218.	3.2	18
180	Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study. Current Medical Research and Opinion, 2005, 21, 645-655.	2.0	17

#	Article	IF	Citations
181	MLL amplification in acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2007, 174, 127-131.	1.0	17
182	Cost-effectiveness of posaconazole versusfluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. BMC Infectious Diseases, 2012, 12, 83.	3.0	17
183	Results of a preoperative autologous blood donation program for patients undergoing elective major spine surgery. Transfusion and Apheresis Science, 2013, 49, 345-348.	1.0	17
184	Response to Plasma Exchange and Steroids as Combined Therapy for Patients with Thrombotic Thrombocytopenic Purpura. Acta Haematologica, 1999, 102, 12-16.	1.4	16
185	Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34+Cell Yields. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 705-709.	1.9	16
186	Current treatment of acute promyelocytic leukemia. Haematologica, 2007, 92, 289-291.	3.5	16
187	A Study of Incidence and Characteristics of Infections in 476 Patients from a Single Center Undergoing Autologous Blood Stem Cell Transplantation. International Journal of Hematology, 2007, 86, 186-192.	1.6	16
188	Biology and management of therapy-related acute promyelocytic leukemia. Current Opinion in Oncology, 2013, 25, 695-700.	2.5	16
189	T Cellâ€“Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1060-1063.	2.1	16
190	Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Annals of Hematology, 2014, 93, 43-46.	1.9	16
191	Emerging strategies for the treatment of older patients with acute myeloid leukemia. Annals of Hematology, 2016, 95, 1583-1593.	1.9	16
192	The European LeukemiaNet: achievements and perspectives. Haematologica, 2011, 96, 156-162.	3.5	15
193	Initiation codon selection is accomplished by a scanning mechanism without crucial initiation factors in Sindbis virus subgenomic mRNA. Rna, 2015, 21, 93-112.	3.6	15
194	Role of bone marrow biopsy in staging of patients with classical Hodgkinâ€™s lymphoma undergoing positron emission tomography/computed tomography. Annals of Hematology, 2017, 96, 1147-1153.	1.9	15
195	Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. Experimental Hematology, 2018, 62, 24-32.	0.5	15
196	Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain. Journal of Infection and Chemotherapy, 2019, 25, 605-609.	1.7	15
197	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. European Journal of Haematology, 2020, 105, 138-147.	2.3	15
198	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. HemaSphere, 2021, 5, e617.	2.4	15

#	Article	IF	Citations
199	Liver disease as primary manifestation of multiple myeloma in a young man. Leukemia Research, 1999, 23, 403-405.	1.1	14
200	Unrelated-Donor Cord Blood Transplantation for Adult Hematological Malignancies. Leukemia and Lymphoma, 2004, 45, 11-18.	1.4	14
201	Advances in haploidentical stem cell transplantation for hematologic malignancies. Leukemia and Lymphoma, 2016, 57, 1766-1775.	1.4	14
202	Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain. Antimicrobial Resistance and Infection Control, 2019, 8, 167.	4.4	14
203	Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. Scientific Reports, 2021, 11, 20745.	3.5	14
204	An iminophosphorane-based approach for the synthesis of spiropyrrolidineâ€“imidazole derivatives. Tetrahedron, 2007, 63, 1849-1856.	2.0	13
205	Influence of storage conditions on the sensory quality of a high acid apple. International Journal of Food Science and Technology, 2010, 45, 2352-2357.	2.7	13
206	Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. Annals of Hematology, 2012, 91, 1-7.	1.9	13
207	Prognostic impact of <scp>KMT</scp>2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with allâ€trans retinoic acid and anthracyclineâ€based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. British Journal of Haematology, 2014, 166, 540-549.	2.8	13
208	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia and Lymphoma, 2019, 60, 1146-1155.	1.4	13
209	Evolving treatment patterns and outcomes in older patients (â‰¥60 years) with AML: changing everything to change nothing?. Leukemia, 2021, 35, 1571-1585.	7.5	13
210	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer Journal, 2021, 11, 167.	6.4	13
211	Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leukemia Research, 2001, 25, 685-692.	1.1	12
212	Tratamiento de las infecciones fÃºngicas en pacientes con neoplasias hematolÃ³gicas. Medicina ClÃnica, 2009, 132, 507-521.	0.6	12
213	Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting. Journal of Molecular Diagnostics, 2012, 14, 594-601.	3.0	12
214	WT1 isoform expression pattern in acute myeloid leukemia. Leukemia Research, 2013, 37, 1744-1749.	1.1	12
215	The role of SWRO Barcelona-Llobregat Plant in the water supply system of Barcelona Area. Desalination and Water Treatment, 2013, 51, 111-123.	1.0	12
216	Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer Journal, 2017, 7, 630.	6.4	12

#	Article	IF	Citations
217	Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model. Human Reproduction, 2019, 34, 1485-1493.	1.0	12
218	The Pre-Treatment C-Reactive Protein Represents a Prognostic Factor in Patients with Oral and Oropharyngeal Cancer Treated with Radiotherapy. Cancers, 2020, 12, 626.	3.9	12
219	Outcome and Prognostic Factors after Unrelated Donor Umbilical Cord Blood Transplantation in Adult Patients with Hematologic Malignancies Transplanted in Early Disease Stages.. Blood, 2004, 104, 2149-2149.	1.4	12
220	3 Immunophenotyping of AML and MDS and detection of residual disease. Best Practice and Research: Clinical Haematology, 1996, 9, 35-55.	1.0	11
221	Phosphorylation of eIF2Î± is responsible for the failure of the picornavirus internal ribosome entry site to direct translation from Sindbis virus replicons. Journal of General Virology, 2013, 94, 796-806.	3.0	11
222	Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study. Transfusion Medicine and Hemotherapy, 2018, 45, 162-166.	1.5	11
223	History of Acute Promyelocytic Leukemia. Clinical Hematology International, 2021, 3, 142.	1.9	11
224	Recomendaciones del Grupo EspaÃ±ol de PTI para el diagnÃ³stico, tratamiento y seguimiento de pacientes con trombocitopenia inmune. Medicina ClÃnica, 2021, 157, 191-198.	0.6	11
225	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. Blood, 2009, 114, 6-6.	1.4	11
226	Membrane-permeabilizing motif in Semliki forest virus E1 glycoprotein. FEBS Letters, 2004, 576, 417-422.	2.8	10
227	Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. Leukemia Research, 2005, 29, 595-597.	1.1	10
228	Treatment of Patients With Acute Promyelocytic Leukemia: A Consensus Statement on Risk-Adapted Approaches to Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S122-S126.	0.4	10
229	Acute Promyelocytic Leukemia: Do We Have a New Front-Line Standard of Treatment?. Current Oncology Reports, 2013, 15, 445-449.	4.2	10
230	Inhibition of host protein synthesis by Sindbis virus: correlation with viral RNA replication and release of nuclear proteins to the cytoplasm. Cellular Microbiology, 2015, 17, 520-541.	2.3	10
231	Study of the S427G polymorphism and ofMYBL2variants in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 429-435.	1.4	10
232	A viral RNA motif involved in signaling the initiation of translation on non-AUG codons. Rna, 2019, 25, 431-452.	3.6	10
233	MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients. International Journal of Molecular Sciences, 2020, 21, 2714.	4.2	10
234	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood, 1997, 90, 4710-4718.	1.4	10

#	Article	IF	Citations
235	Unrelated Donor Umbilical Cord Blood Transplantation (UD-UCBT) for Adult Patients with High-Risk Acute Myeloid Leukemia (AML). Blood, 2008, 112, 4401-4401.	1.4	10
236	Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 5677.	3.9	10
237	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1389-1398.	2.5	10
238	TWO TYPES OF ACQUIRED IDIOPATHIC SIDEROBLASTIC ANAEMIA. British Journal of Haematology, 1990, 75, 633-634.	2.8	9
239	A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemia. Cancer Genetics and Cytogenetics, 2006, 168, 73-76.	1.0	9
240	High-level amplification of the RUNX1 gene in two cases of childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2006, 170, 171-174.	1.0	9
241	Long-term management of chronic immune thrombocytopenic purpura in adults. International Journal of General Medicine, 2010, 3, 305.	1.8	9
242	Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. Leukemia Research, 2011, 35, 479-483.	1.1	9
243	A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Current Medical Research and Opinion, 2012, 28, 789-796.	2.0	9
244	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. Blood Advances, 2017, 1, 1047-1055.	5.5	9
245	Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. Haematologica, 2018, 103, e400-e403.	3.5	9
246	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. Annals of Hematology, 2019, 98, 2467-2483.	1.9	9
247	An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. Leukemia and Lymphoma, 2019, 60, 1030-1035.	1.4	9
248	Adoptive transfer of ex vivo expanded SARSâ€CoVâ€2â€specific cytotoxic lymphocytes: A viable strategy for COVIDâ€19 immunosuppressed patients?. Transplant Infectious Disease, 2021, 23, e13602.	1.7	9
249	pT1 Colorectal Cancer Detected in a Colorectal Cancer Mass Screening Program: Treatment and Factors Associated with Residual and Extraluminal Disease. Cancers, 2020, 12, 2530.	3.9	9
250	Genotype and environment effects on sensory, nutritional, and physical traits in chickpea (Cicer) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	0.6	9
251	MONOSOMY 7 AND ACUTE MIXED LEUKAEMIA. British Journal of Haematology, 1986, 64, 842-844.	2.8	8
252	Quantitative Assessment of PML-RARa and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial. Clinical Chemistry, 2004, 50, 1088-1092.	3.5	8

#	Article	IF	Citations
253	Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients. Annals of Hematology, 2012, 91, 1845-1853.	1.9	8
254	Novel Real-Time Polymerase Chain Reaction Assay for Simultaneous Detection of Recurrent Fusion Genes in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2013, 15, 678-686.	3.0	8
255	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. Annals of Hematology, 2017, 96, 1077-1084.	1.9	8
256	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. Blood Advances, 2017, 1, 1807-1814.	5.5	8
257	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. Cancers, 2018, 10, 436.	3.9	8
258	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. Cancers, 2020, 12, 3134.	3.9	8
259	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation. Journal of Infection, 2020, 80, 333-341.	3.4	8
260	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. Scientific Reports, 2020, 10, 5904.	3.5	8
261	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. Cancers, 2021, 13, 2458.	3.9	8
262	Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers, 2022, 14, 2342.	3.9	8
263	Autologous peripheral blood stem cell transplantation for acute leukaemias. Best Practice and Research in Clinical Haematology, 1999, 12, 139-150.	1.9	7
264	Locked Nucleic Acid-Enhanced Detection of 1100delC*CHEK2 Germ-Line Mutation in Spanish Patients with Hematologic Malignancies. Clinical Chemistry, 2004, 50, 2201-2204.	3.5	7
265	Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study. Biology of Blood and Marrow Transplantation, 2009, 15, 512-516.	2.1	7
266	Significance of Increased Blastic-Appearing Cells in Bone Marrow Following Myeloablative Unrelated Cord Blood Transplantation in Adult Patients. Biology of Blood and Marrow Transplantation, 2012, 18, 388-395.	2.1	7
267	Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia. PLoS ONE, 2014, 9, e100245.	2.4	7
268	Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. Clinical Case Reports (discontinued), 2017, 5, 1887-1890.	0.5	7
269	Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia. Frontiers in Oncology, 2021, 11, 614215.	3.0	7
270	Body mass index and survival of patients with lymphoma. Leukemia and Lymphoma, 2021, 62, 2671-2678.	1.4	7

#	Article	IF	Citations
271	A Comprehensive Survey of Readout Strategies for SiPMs Used in Nuclear Imaging Systems. Photonics, 2021, 8, 266.	2.1	7
272	Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL. Blood, 2010, 116, 15-15.	1.4	7
273	All-Trans Retinoic ACID and Low-Dose Chemotherapy For Acute Promyelocytic Leukaemia. British Journal of Haematology, 2000, 109, 896-897.	2.8	6
274	Risk-Adapted Treatment for Low- and Intermediate-Risk Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S130-S134.	0.4	6
275	Effect of cultivar and roasting technique on sensory quality of Bierzo roasted pepper. Journal of the Science of Food and Agriculture, 2011, 91, 2426-2430.	3.6	6
276	RNA Sequencing Analysis for the Identification of a <i>PCM1/PDGFRB</i> Fusion Gene Responsive to Imatinib. Acta Haematologica, 2019, 142, 92-97.	1.4	6
277	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. European Journal of Haematology, 2020, 104, 162-169.	2.3	6
278	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplantation, 2020, 55, 2244-2253.	2.5	6
279	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graftâ€versusâ€host disease prophylaxis. EJHaem, 2021, 2, 236-248.	1.0	6
280	A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms. Cancers, 2021, 13, 1947.	3.9	6
281	Incidence, Outcome and Risk Factors of Pseudotumor Cerebri after All- Trans Retinoic Acid and Anthracycline-Based Chemotherapy in Patients with Acute Promyelocytic Leukemia. Blood, 2008, 112, 2992-2992.	1.4	6
282	BONE MARROW ASSESSMENT IN Bâ€CELL CHRONIC LYMPHOCYTIC LEUKAEMIA: ASPIRATE OR BIOPSY?. British Journal of Haematology, 1996, 95, 754-755.	2.8	5
283	The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). Hematology, 2012, 17, s36-s38.	1.6	5
284	Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia. Annals of Hematology, 2012, 91, 19-25.	1.9	5
285	Conventional induction and post-remission therapy in APL: Have we arrived?. Best Practice and Research in Clinical Haematology, 2014, 27, 33-38.	1.9	5
286	Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study. Hematology, 2017, 22, 1-9.	1.6	5
287	The modular network structure of the mutational landscape of Acute Myeloid Leukemia. PLoS ONE, 2018, 13, e0202926.	2.4	5
288	Comparison of transfusion requirements in adult patients undergoing Haploidentical or singleâ€unit umbilical cord blood stem cell transplantation. European Journal of Haematology, 2019, 103, 172-177.	2.3	5

#	Article	IF	Citations
289	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 105-113.	0.4	5
290	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Scientific Reports, 2020, 10, 10315.	3.5	5
291	Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia. Pharmacogenetics and Genomics, 2021, 31, 133-139.	1.5	5
292	Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. Transplantation and Cellular Therapy, 2021, 27, 311.e1-311.e10.	2.6	5
293	Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.. Blood, 2004, 104, 2019-2019.	1.4	5
294	Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.. Blood, 2004, 104, 394-394.	1.4	5
295	Evaluation of AMG 531 Efficacy in Nonsplenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.. Blood, 2007, 110, 565-565.	1.4	5
296	Activity and Safety of Lenalidomide and Dexamethasone in Multiple Myeloma Patients with Advanced Renal Failure: a Spanish Multicenter Retrospective Study.. Blood, 2009, 114, 1886-1886.	1.4	5
297	NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. Oncotarget, 2017, 8, 76003-76014.	1.8	5
298	Manejo del paciente neutropÃ©nico con fiebre. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2005, 23, 24-29.	0.6	4
299	Effect of storage conditions on sensory properties of Bierzo roasted pepper. Journal of the Science of Food and Agriculture, 2011, 91, 80-84.	3.6	4
300	Impact of Myeloablative and Reduced Intensity Conditioning on Outcomes After Unrelated Cord Blood Transplantation for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2013, 19, S127.	2.1	4
301	Screening forIDHmutations in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2013, 54, 406-407.	1.4	4
302	A retrospective audit of platelet transfusion in a hematology service of a tertiary-care hospital: Effectiveness of training to improve compliance with standards. Transfusion and Apheresis Science, 2014, 50, 228-229.	1.0	4
303	Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment. Revista Iberoamericana De Micologia, 2015, 32, 185-189.	1.0	4
304	Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 2931-2938.	1.4	4
305	Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen. European Journal of Haematology, 2019, 102, 331-340.	2.3	4
306	High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous Î²-Lactams. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	4

#	Article	IF	Citations
307	Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation. Bone Marrow Transplantation, 2020, 55, 2261-2269.	2.5	4
308	Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study. Cancers, 2020, 12, 969.	3.9	4
309	Ex vivo Tâ€cell depletion vs postâ€transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graftâ€vsâ€host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2021, 106, 114-125.	2.3	4
310	Central Nervous System Involvement in Epsteinâ€“Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 261.e1-261.e7.	2.6	4
311	Long-term Survival in Chronic Neutrophilic Leukemia. American Journal of Clinical Pathology, 1980, 74, 717.1-717.	0.8	3
312	Molecular detection of Spanish ÎÎ²-thalassemia associated with Î²-thalassemia identified during prenatal diagnosis. Clinica Chimica Acta, 2006, 368, 195-198.	1.6	3
313	Absence of mutations in the tyrosine kinase and juxtamembrane domains of C-FMS gene in chronic myelomonocytic leukemia (CMML). Leukemia Research, 2009, 33, e162-e163.	1.1	3
314	A new reliable fluorescencein situhybridization method for identifying multiple specific cytogenetic abnormalities in acute myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 680-685.	1.4	3
315	Treatment of multiple myeloma in the elderly: realities and hopes. Leukemia and Lymphoma, 2011, 52, 9-14.	1.4	3
316	DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019016.	1.1	3
317	Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain. PharmacoEconomics - Open, 2019, 3, 229-235.	1.9	3
318	Validation of a multivariable prediction model for postâ€engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. Mycoses, 2019, 62, 418-427.	4.2	3
319	Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, 83-87.	2.1	3
320	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). Blood, 2018, 132, 435-435.	1.4	3
321	Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH). Blood, 2015, 126, 4399-4399.	1.4	3
322	Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGA. Blood, 2016, 128, 448-448.	1.4	3
323	Revealing the mutational landscape of acute promyelocytic leukemia. Translational Cancer Research, 2017, 6, S127-S130.	1.1	3
324	Bolus of Methylprednisolone for Aplastic Anemia. Annals of Internal Medicine, 1982, 96, 124.	9.7	3

#	Article	IF	Citations
325	Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers. Blood, 2019, 134, 2352-2352.	1.4	3
326	Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. Blood, 2020, 136, 25-27.	1.4	3
327	Acute Promyelocytic Leukaemia. Relationship of Cytochemical Pattern with Clinical, Morphologic and Immunological Characteristics, and Outcome. Leukemia and Lymphoma, 1990, 2, 85-92.	1.4	2
328	Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?. Leukemia Research, 2007, 31, 1315-1317.	1.1	2
329	Indicaciones actuales de voriconazol en pacientes onco-hematolÃ³gicos. Revista Iberoamericana De Micologia, 2007, 24, 213-216.	1.0	2
330	Utilidad clÃ¬nica de la micafungina en el tratamiento de las candidiasis invasoras en el paciente oncohematolÃ³gico. Revista Iberoamericana De Micologia, 2009, 26, 75-77.	1.0	2
331	Update on bacteraemia in oncology and hematology. Enfermedades Infecciosas Y MicrobiologÃa ClÃ¬nica, 2011, 29, 48-53.	0.6	2
332	Whole-Genome Sequencing and Acute Promyelocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 306, 610.	7.1	2
333	The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia. British Journal of Haematology, 2018, 180, 915-918.	2.8	2
334	Real life outcomes of patients aged â‰¥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leukemia and Lymphoma, 2019, 60, 2720-2732.	1.4	2
335	Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial. Blood, 2018, 132, 433-433.	1.4	2
336	Low Transplant-Related Mortality in Patients with Hematologic Malignancies Undergoing Umbilical Cord Blood Transplantation (UCBT) with Thiotepa (TT), Once-Daily Intravenous (IV) Busulfan (BU), Fludarabine (FLU) and Anti-Thymocyte Globulin (ATG).. Blood, 2007, 110, 618-618.	1.4	2
337	Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Results of the PETHEMA LPA2005 Trial Using All-Trans Retinoic Acid and Anthracycline with Cytarabine for High-Risk Patients. Blood, 2008, 112, 138-138.	1.4	2
338	Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL. Blood, 2008, 112, 139-139.	1.4	2
339	Gene Microdeletions in Adult and Pediatric Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3539-3539.	1.4	2
340	RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT. Blood, 2014, 124, 545-545.	1.4	2
341	Long-Term Follow up of Healthy Donors Receiving G-CSF for Peripheral Blood Progenitor Cell Mobilization and Collection.. Blood, 2005, 106, 1975-1975.	1.4	2
342	FLAG-IDA Regimen (Fludarabine, Cytarabine, Idarubicin and G-CSF) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes.. Blood, 2007, 110, 2866-2866.	1.4	2

#	Article	IF	Citations
343	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. Blood, 2015, 126, 172-172.	1.4	2
344	Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study. Blood, 2016, 128, 1614-1614.	1.4	2
345	Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia, , Abstracted from: Avvisati G, Petti M, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study, LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (9): 3141â€“6., Cancer Treatment Reviews, 2003, 29, 143-146.	8.1	1
346	Profilaxis antifÃºngica en pacientes oncohematolÃ³gicos: revisiÃ³n de la bibliografÃa mÃ©dica y recomendaciones. Medicina ClÃnica, 2010, 134, 222-233.	0.6	1
347	Quality of thawed plasma inactivated with methylene blue after 48-hour storage. Transfusion and Apheresis Science, 2015, 52, 141-142.	1.0	1
348	Intimate Partner Violence in Adolescence: Associations With Perpetration Trauma, Rumination, and Posttraumatic Stress. Journal of Interpersonal Violence, 2019, 36, 088626051984878.	2.2	1
349	Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombocytopenia. Medicina ClÃnica (English Edition), 2021, 157, 191-198.	0.2	1
350	Causes of Induction Failure in Newly Diagnosed Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Idarubicin (AIDA).. Blood, 2004, 104, 887-887.	1.4	1
351	Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Updated Results of the Spanish PETHEMA LPA99 Trial Using ATRA and Anthracycline Monochemotherapy.. Blood, 2007, 110, 590-590.	1.4	1
352	Central Nervous System Relapse in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Reinforced Anthracycline Monochemotherapy.. Blood, 2007, 110, 592-592.	1.4	1
353	CD34+ Cell Dose Is the Major Cell Dose Determinant of Myeloid Engraftment After Single Umbilical Cord Blood Transplantation (sUCBT) for Adult Patients with High-Risk Hematologic Malignancies. Blood, 2010, 116, 1339-1339.	1.4	1
354	Outcomes In Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation Using Intravenous Busulfan and Melphalan: A Matched Comparison to a Double Autologous Transplant Strategy. Blood, 2010, 116, 3560-3560.	1.4	1
355	A Prognostic Index for Patients with Refractory or in First Relapsed Acute Myeloid Leukemia Treated with FLAG-Ida or Flago-Ida. Blood, 2014, 124, 1049-1049.	1.4	1
356	Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults. Blood, 2014, 124, 2237-2237.	1.4	1
357	Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party. Blood, 2014, 124, 2573-2573.	1.4	1
358	Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses. Blood, 2014, 124, 3751-3751.	1.4	1
359	Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia. Blood, 2015, 126, 4842-4842.	1.4	1
360	Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia. Blood, 2015, 126, 4845-4845.	1.4	1

#	Article	IF	Citations
361	Unrelated Donor Umbilical Cord Blood Transplantation (UD-UCBT) for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (ALL).. Blood, 2007, 110, 2024-2024.	1.4	1
362	Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.. Blood, 2009, 114, 1062-1062.	1.4	1
363	Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups.. Blood, 2009, 114, 845-845.	1.4	1
364	Intravenous Busulfan (IV Bu)-Based Conditioning Regimen Before Allogeneic Stem Cell Transplantation (allo-SCT) for Adults with Acute Lymphoid Leukemia (ALL): A Aurvey From the Acute Leukemia Working Party of EBMT. Blood, 2011, 118, 3005-3005.	1.4	1
365	A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia. Blood, 1999, 94, 3694-3701.	1.4	1
366	A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group. Blood, 2019, 134, 648-648.	1.4	1
367	Impact of Sociodemographic and Clinical Factors on the Survival of Patients with Acute Myeloid Leukemia: A Multicenter Experience in Colombia, on Behalf of Acho's Renehoc-Pethema Investigators. Blood, 2021, 138, 3374-3374.	1.4	1
368	Effect of Sustainable Preharvest and Postharvest Techniques on Quality and Storability of High-Acidity â€˜Reinette du Canadaâ€™ Apple. Horticulturae, 2022, 8, 86.	2.9	1
369	Effect of Fruit Weight and Fruit Locule Number in Bell Pepper on Industrial Waste and Quality of Roasted Pepper. Horticulturae, 2022, 8, 455.	2.9	1
370	Validation of survival-predictive models in myelodysplastic syndromes. American Journal of Hematology, 1989, 30, 44-44.	4.3	0
371	PROGNOSTIC IRRELEVANCE OF CD34 IN ACUTE MYELOID LEUKAEMIA. British Journal of Haematology, 1992, 82, 480-480.	2.8	0
372	Update on pulmonary infections in patients with hematologic malignancies and hematopoietic stem cell recipients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2008, 26, 58-71.	0.6	0
373	Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). Leukemia Research, 2012, 36, e50-e51.	1.1	0
374	Efficient Identification of Response to Cytarabine Idarubicin in Newly Diagnosed Acute Myeloid Leukemia by a New Individualized Medicine Test Based on ex vivo Pharmacology. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S118-S119.	0.4	0
375	1st Line AML Equivalent Treatments Cytarabine Plus an Anthracyclin (Ida, Dau, Mit) Show Alternative Sensitive/Resistant Profiles in ex vivo Patient Sample Chemosensitivity; Could Personalizing be the Key Selection Criterion?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S117-S118.	0.4	0
376	Comparison of Single Unmanipulated Umbilical Cord Blood or Co-Infusion of an Umbilical Cord Blood Graft with CD34+ Cells From a Third Party Donor in Adults with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, S123-S124.	2.1	0
377	Hematopoietic Stem Cell Transplantation in APL. , 2018, , 171-177.		0
378	Prognostic Factors in APL. , 2018, , 87-98.		0

#	Article	IF	Citations
379	Special Situations in APL. , 2018, , 203-210.		0
380	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Leukemia and Lymphoma, 2021, 62, 2727-2736.	1.4	0
381	Military dictatorship as the â€˜reign of the mightierâ€™. , 2021, , 66-81.		0
382	Real-Time Quantification of the AML Rearrangements, AML1-ETO and TEL-AML1, in Acute Leukemia. , 2004, , 141-155.		0
383	PML/RARÎ± Mediates Resistance to Apoptosis and Down-Regulation of the NF-Î²B Pathway in Acute Promyelocytic Leukemia.. Blood, 2004, 104, 4283-4283.	1.4	0
384	Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.. Blood, 2004, 104, 3430-3430.	1.4	0
385	Prophylaxis of Cytomegalovirus (CMV) Infection and Disease after Unrelated-Donor Umbilical Cord-Blood Transplantation (UCBT) with Intravenous Ganciclovir or Oral Valganciclovir.. Blood, 2005, 106, 5460-5460.	1.4	0
386	SHP-1 (PTPN6) Gene Supression by FLT3/ITD Defines an Aggressive Subgroup of Myeloid Malignancies.. Blood, 2006, 108, 1907-1907.	1.4	0
387	Long-Term Outcome and Prognostic Factors after Single-Unit Umbilical Cord-Blood Transplantation (UCBT) for Adults with Hematologic Malignancies.. Blood, 2006, 108, 3129-3129.	1.4	0
388	Outcome of Patients with Primary Refractory Acute Myeloid Leukemia (AML) Undergoing Myeloablative Allogeneic Stem-Cell Transplantation (alloSCT) from HLA-Identical Sibling: Favorable Outcome in a Subset of Patients.. Blood, 2006, 108, 3022-3022.	1.4	0
389	Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.. Blood, 2007, 110, 4928-4928.	1.4	0
390	Unrelated Transplants for Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Comparative Analysis Based on the Hematopoietic Progenitor Source.. Blood, 2008, 112, 969-969.	1.4	0
391	Treatment with All-Trans Retinoic Acid and Anthracycline Monochemotherapy in Children with Acute Promyelocytic Leukemia: Analysis of Three Sequential Multicenter Trials of the PETHEMA Group. Blood, 2008, 112, 137-137.	1.4	0
392	Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.. Blood, 2008, 112, 1649-1649.	1.4	0
393	Epigenomic Analysis of Acute Myeloid Leukemia Identifies Specific Patterns and Markes with Clinical and Biological Relevance.. Blood, 2009, 114, 2394-2394.	1.4	0
394	Assessment of Safety and Efficacy of a New Intravenous Immunoglobulin (IGIV3I 10% Grifols) In Subjects with Chronic Immune Thrombocytopenia. Blood, 2010, 116, 4669-4669.	1.4	0
395	The Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,. Blood, 2011, 118, 4139-4139.	1.4	0
396	Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT. Blood, 2011, 118, 3056-3056.	1.4	0

#	Article	IF	Citations
397	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,. Blood, 2011, 118, 3552-3552.	1.4	0
398	Î”Np73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,. Blood, 2011, 118, 3536-3536.	1.4	0
399	Quantitative Expression Analysis of WT1 Main Isoforms in AML. Blood, 2011, 118, 1469-1469.	1.4	0
400	Analysis of ASXL1, IDH1, IDH2, c-CBL, and WT1 Mutations in De Novo Acute Myeloid Leukaemia. Blood, 2011, 118, 1450-1450.	1.4	0
401	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2012, 120, 1407-1407.	1.4	0
402	Impact of Myeloablative and Reduced Intensity Conditioning On Outcomes After Unrelated Cord Blood Transplantation for Adults with Acute Lymphoblastic Leukemia.. Blood, 2012, 120, 3117-3117.	1.4	0
403	Prognostic Value of Complex Karyotype and Monosomal Karyotype in Patients with Adult Acute Lymphoblastic Leukemia Treated with Risk-Adapted Protocols. Blood, 2012, 120, 4785-4785.	1.4	0
404	Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML). Blood, 2012, 120, 1512-1512.	1.4	0
405	Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine. Blood, 2013, 122, 1347-1347.	1.4	0
406	The Interaction Between Collagen-Activated Platelets and Erythrocytes Selectively Increases the Release of Subsets of Platelet Î±-Granules Containing Pro-Angiogenic Substances. Blood, 2014, 124, 4171-4171.	1.4	0
407	Novel Assay for Ex Vivo Evaluation of Antiproliferative Effect of Hypomethylating Agents 5-Azacytidine and Decitabine in AML Patient Samples. Blood, 2014, 124, 5311-5311.	1.4	0
408	Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy. Blood, 2014, 124, 5223-5223.	1.4	0
409	Validation of a Next-Generation Sequencing Panel for AML Routine Diagnosis. Blood, 2015, 126, 1403-1403.	1.4	0
410	Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice. Blood, 2015, 126, 2263-2263.	1.4	0
411	Efficacy and Safety of Eltrombopag in Persistent and Newly Diagnosed ITP. Blood, 2015, 126, 4657-4657.	1.4	0
412	High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test. Blood, 2015, 126, 4837-4837.	1.4	0
413	Comparative Study of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation Versus Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4358-4358.	1.4	0
414	NCCN-IPI in Patients with Diffuse Large B CELL Lymphoma Treated with DA-R-EPOCH. Retrospective Analysis. Blood, 2016, 128, 5401-5401.	1.4	0

#	Article	IF	Citations
415	Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing. Blood, 2016, 128, 598-598.	1.4	0
416	Influence of Cytarabine Metabolic Pathway Polymorphisms in Acute Myeloid Leukemia Induction Treatment. Blood, 2016, 128, 5130-5130.	1.4	0
417	Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables. Blood, 2016, 128, 3802-3802.	1.4	0
418	Preliminary Results of the Flugaza Trial: A Phase III Randomized, Open Label Study Comparing Azacytidine Versus Fludarabine and Cytarabine (FLUGA Scheme) in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2016, 128, 4036-4036.	1.4	0
419	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide â€" an International Collaborative Study. Blood, 2018, 132, 80-80.	1.4	0
420	Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy+ Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy. Blood, 2018, 132, 5764-5764.	1.4	0
421	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. Blood, 2018, 132, 1533-1533.	1.4	0
422	Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. Blood, 2018, 132, 1532-1532.	1.4	0
423	Molecular Genetics of Acute Promyelocytic Leukaemia. , 0, , 1-8.		0
424	Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry. Blood, 2019, 134, 1321-1321.	1.4	0
425	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 2719-2719.	1.4	0
426	Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial. Blood, 2019, 134, 3891-3891.	1.4	0
427	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 5166-5166.	1.4	0
428	Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group. Blood, 2021, 138, 1302-1302.	1.4	0
429	Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry. Blood, 2021, 138, 1255-1255.	1.4	0
430	Venetoclax Therapy in a Heavily Treated Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Update of the Pethema Registry Experience. Blood, 2021, 138, 2325-2325.	1.4	0
431	Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML). Blood, 2021, 138, 520-520.	1.4	0
432	Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. Blood, 2021, 138, 1256-1256.	1.4	0

#	Article	IF	Citations
433	Understanding Learners Behavior in Massive Open Online Courses. , 2020, , .		0
434	Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience. Blood, 2020, 136, 2-3.	1.4	0
435	Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. Cancers, 2022, 14, 2817.	3.9	0